Cargando…

Clinical efficacy analysis of paxlovid in children with hematological diseases infected with the omicron SARS-CoV-2 new variant

OBJECTIVE: To summarize the clinical characteristics of children with hematological malignancies co-infected with novel coronavirus and explore the safety and effectiveness of Paxlovid treatment. METHODS: From December 10, 2022, to January 20, 2023, the clinical data of children with hematological d...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yixian, Liu, Yong, Wen, Luping, Chen, Hui, Wang, Wenqing, Tian, Mengyao, Cheng, Yucai, Xue, Hongman, Chen, Chun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10167044/
https://www.ncbi.nlm.nih.gov/pubmed/37181421
http://dx.doi.org/10.3389/fped.2023.1160929
_version_ 1785038579404111872
author Li, Yixian
Liu, Yong
Wen, Luping
Chen, Hui
Wang, Wenqing
Tian, Mengyao
Cheng, Yucai
Xue, Hongman
Chen, Chun
author_facet Li, Yixian
Liu, Yong
Wen, Luping
Chen, Hui
Wang, Wenqing
Tian, Mengyao
Cheng, Yucai
Xue, Hongman
Chen, Chun
author_sort Li, Yixian
collection PubMed
description OBJECTIVE: To summarize the clinical characteristics of children with hematological malignancies co-infected with novel coronavirus and explore the safety and effectiveness of Paxlovid treatment. METHODS: From December 10, 2022, to January 20, 2023, the clinical data of children with hematological diseases diagnosed with novel coronavirus infection in the outpatient and emergency department of the Seventh Affiliated Hospital of Sun Yat-sen University were retrospectively analyzed. RESULTS: According to whether to give paxlovid or not, it is divided into group A (paxlovid group) and group B (non-paxlovid group). The length of fever was 1–6 days in group A and 0–3 days in group B. The viral clearance time was shorter in group A than in group B. The inflammatory indexes CRP and PCT were significantly higher in group A than in group B (P < 0.05). Twenty patients were followed up for 1 month after leaving the hospital, and there were 5 cases of reappearance of fever, 1 case of increased sleep, 1 case of physical fatigue and 1 case of loss of appetite within 2 weeks. CONCLUSIONS: Paxlovid has no apparent adverse reactions in children 12 years old and younger with underlying hematological diseases infected with the new coronavirus. Focusing on the interaction between paxlovid and other drugs is necessary during the treatment.
format Online
Article
Text
id pubmed-10167044
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101670442023-05-10 Clinical efficacy analysis of paxlovid in children with hematological diseases infected with the omicron SARS-CoV-2 new variant Li, Yixian Liu, Yong Wen, Luping Chen, Hui Wang, Wenqing Tian, Mengyao Cheng, Yucai Xue, Hongman Chen, Chun Front Pediatr Pediatrics OBJECTIVE: To summarize the clinical characteristics of children with hematological malignancies co-infected with novel coronavirus and explore the safety and effectiveness of Paxlovid treatment. METHODS: From December 10, 2022, to January 20, 2023, the clinical data of children with hematological diseases diagnosed with novel coronavirus infection in the outpatient and emergency department of the Seventh Affiliated Hospital of Sun Yat-sen University were retrospectively analyzed. RESULTS: According to whether to give paxlovid or not, it is divided into group A (paxlovid group) and group B (non-paxlovid group). The length of fever was 1–6 days in group A and 0–3 days in group B. The viral clearance time was shorter in group A than in group B. The inflammatory indexes CRP and PCT were significantly higher in group A than in group B (P < 0.05). Twenty patients were followed up for 1 month after leaving the hospital, and there were 5 cases of reappearance of fever, 1 case of increased sleep, 1 case of physical fatigue and 1 case of loss of appetite within 2 weeks. CONCLUSIONS: Paxlovid has no apparent adverse reactions in children 12 years old and younger with underlying hematological diseases infected with the new coronavirus. Focusing on the interaction between paxlovid and other drugs is necessary during the treatment. Frontiers Media S.A. 2023-04-25 /pmc/articles/PMC10167044/ /pubmed/37181421 http://dx.doi.org/10.3389/fped.2023.1160929 Text en © 2023 Li, Liu, Wen, Chen, Wang, Tian, Cheng, Xue and Chen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pediatrics
Li, Yixian
Liu, Yong
Wen, Luping
Chen, Hui
Wang, Wenqing
Tian, Mengyao
Cheng, Yucai
Xue, Hongman
Chen, Chun
Clinical efficacy analysis of paxlovid in children with hematological diseases infected with the omicron SARS-CoV-2 new variant
title Clinical efficacy analysis of paxlovid in children with hematological diseases infected with the omicron SARS-CoV-2 new variant
title_full Clinical efficacy analysis of paxlovid in children with hematological diseases infected with the omicron SARS-CoV-2 new variant
title_fullStr Clinical efficacy analysis of paxlovid in children with hematological diseases infected with the omicron SARS-CoV-2 new variant
title_full_unstemmed Clinical efficacy analysis of paxlovid in children with hematological diseases infected with the omicron SARS-CoV-2 new variant
title_short Clinical efficacy analysis of paxlovid in children with hematological diseases infected with the omicron SARS-CoV-2 new variant
title_sort clinical efficacy analysis of paxlovid in children with hematological diseases infected with the omicron sars-cov-2 new variant
topic Pediatrics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10167044/
https://www.ncbi.nlm.nih.gov/pubmed/37181421
http://dx.doi.org/10.3389/fped.2023.1160929
work_keys_str_mv AT liyixian clinicalefficacyanalysisofpaxlovidinchildrenwithhematologicaldiseasesinfectedwiththeomicronsarscov2newvariant
AT liuyong clinicalefficacyanalysisofpaxlovidinchildrenwithhematologicaldiseasesinfectedwiththeomicronsarscov2newvariant
AT wenluping clinicalefficacyanalysisofpaxlovidinchildrenwithhematologicaldiseasesinfectedwiththeomicronsarscov2newvariant
AT chenhui clinicalefficacyanalysisofpaxlovidinchildrenwithhematologicaldiseasesinfectedwiththeomicronsarscov2newvariant
AT wangwenqing clinicalefficacyanalysisofpaxlovidinchildrenwithhematologicaldiseasesinfectedwiththeomicronsarscov2newvariant
AT tianmengyao clinicalefficacyanalysisofpaxlovidinchildrenwithhematologicaldiseasesinfectedwiththeomicronsarscov2newvariant
AT chengyucai clinicalefficacyanalysisofpaxlovidinchildrenwithhematologicaldiseasesinfectedwiththeomicronsarscov2newvariant
AT xuehongman clinicalefficacyanalysisofpaxlovidinchildrenwithhematologicaldiseasesinfectedwiththeomicronsarscov2newvariant
AT chenchun clinicalefficacyanalysisofpaxlovidinchildrenwithhematologicaldiseasesinfectedwiththeomicronsarscov2newvariant